Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 41.00
Ask: 43.00
Change: 1.50 (3.70%)
Spread: 2.00 (4.878%)
Open: 41.50
High: 42.00
Low: 41.50
Prev. Close: 40.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Palintest launches Molendotech bathing water test

15 May 2018 07:00

RNS Number : 9469N
Frontier IP Group plc
15 May 2018
 

RNS REACH / RNS

AIM: FIPP

15 May 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Palintest launches Molendotech bathing water test

 

 

Frontier IP, which specialises in commercialising university intellectual property, today announces that Palintest, a subsidiary of FTSE 100 group Halma plc, is launching Siren BW, a water testing kit developed by portfolio company Molendotech, a spin out from the University of Plymouth.

 

It is the first commercial application for Molendotech's novel test able to identify the concentration of faecal bacteria in water. Currently, it can take two days for local authorities and environmental agencies to assess the quality of recreational water because samples must be sent to a laboratory. Palintest's field-ready kit produces a result in less than 30 minutes and is simple enough to be used at the sample point.

 

The kit is initially available in the UK and Ireland, with roll out to continental Europe and the US planned.

 

Further applications are now being developed in collaboration with Palintest to leverage the real-time availability of pathogen risk in water. It has a wide range of potential uses, including potable water and in food and beverage production.

 

Molendotech was incorporated less than a year ago to develop and commercialise the work of Simon Jackson, Professor of Environment and Human Health within the University of Plymouth's Peninsula Schools of Medicine and Dentistry.

 

Frontier IP chief executive officer Neil Crabb said: "We're delighted the agreement with Palintest, announced earlier this year, is bearing fruit so quickly. It has taken less than a year from Molendotech joining our portfolio to the commercial launch of its first product."

 

Director of Molendotech, Professor Simon Jackson, said: "Water quality is a global issue and fundamental to human and public health. Unfortunately, traditional, lab-based methods for testing water quality, particularly for faecal contamination, do not deliver the kind of rapid results required for in-situ investigation and decision-making. With this breakthrough, however, environmental agencies will be able to gain a much clearer understanding of water quality, which could lead to better and more effective management of beaches and other recreational bathing waters, and faster identification of sources of pollution."

 

Open Innovation Product Manager at Palintest Ian Leahy said: "The opportunity to bring our ability to produce rugged, simple-to-use water quality testing kits together with this exciting Molendotech innovation is a perfect example of two organisations collaborating to answer a clear customer need in the markets we already serve. For many years we sought opportunities to deliver simple, real-time microbiological risk screening at the point of use and I'm excited to say we are finally at that point now."

 

 

For more product details, please contact ian.leahy@palintest.com

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Cenkos Securities plc (Nominated Adviser and Joint Broker)

T: 0131 220 6939

Neil McDonald / Beth McKiernan

 

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

 

Kreab (Financial PR)

T: 020 7074 1800

Robert Speed / Matthew Jervois

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income from by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

Frontier IP and the University of Plymouth:

Frontier IP has forged a strong relationship with the University of Plymouth to commercialise intellectual property. Other collaborations include:

· Fieldwork Robotics: developing advanced soft robotics for harvesting fruit and vegetables. The technology has attracted strong industry interest.

· The Vaccine Group: work includes creating novel vaccines to prevent viruses from jumping the species barrier from animals to humans

· Pulsiv Solar: US and European patents granted on its novel technology to improve the energy efficiency of photovoltaic cells and power conversion

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGIGDUUXBBGIS
Date   Source Headline
30th Nov 20225:00 pmRNSTotal Voting Rights
25th Nov 20222:23 pmRNSDirector/PDMR Shareholding
23rd Nov 20225:17 pmRNSDirector share transfers
18th Nov 20223:53 pmRNSExercise of Options & PDMR Shareholdings
11th Nov 20223:07 pmRNSDirector/PDMR Dealing
11th Nov 20227:00 amRNSPosting of Annual Report and Notice of AGM
8th Nov 20227:00 amRNSPulsiv announces £1.5m fundraise
1st Nov 20221:46 pmEQSFrontier IP Group 'rigged for a storm' but confident of more progress
27th Oct 20227:00 amRNSFinal Results
19th Oct 20224:22 pmRNSHolding(s) in Company
19th Oct 20223:29 pmRNSHolding(s) in Company
14th Oct 20227:00 amRNSElute Intelligence appoints Steve Cable as CEO
27th Sep 20227:00 amRNSPulsiv unveils power electronics technology
18th Aug 20223:20 pmRNSSale of shares in Exscientia
5th Aug 20227:00 amRNSCamGraPhIC announces £1.26 million fundraising
26th Jul 20224:26 pmRNSHolding(s) in Company
26th Jul 20224:07 pmRNSHolding(s) in Company
24th May 20227:00 amRNSCambridge Raman Imaging raises £1.1 million
19th May 20227:00 amRNSPublication of newsletter
12th Apr 20225:18 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSUnaudited Half Year Results
14th Feb 20227:00 amRNSSale of shares in Exscientia
11th Feb 20225:04 pmRNSHolding(s) in Company
11th Feb 20222:05 pmRNSHolding(s) in Company
10th Feb 20227:00 amRNSCambridge Raman Imaging wins European Union grant
25th Jan 20227:00 amRNSSale of shares in Exscientia
17th Jan 20225:56 pmRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update
11th Jan 20227:00 amRNSCelerum launch first commercial product
9th Dec 20212:33 pmRNSResult of AGM
29th Nov 20217:00 amRNSTVG - milestone in development of COVID-19 vaccine
9th Nov 20217:00 amRNSPosting of Annual Accounts and Notice of AGM
28th Oct 20217:00 amRNSDirectorate Change
28th Oct 20217:00 amRNSFinal Results
15th Oct 20217:00 amRNSPublication of newsletter
1st Oct 20217:59 amRNSPricing of IPO of Exscientia in the United States
30th Sep 20217:00 amRNSCamGraPhIC raises £1.6 million
27th Sep 20213:56 pmRNSUpdate on proposed IPO of Exscientia
24th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20217:00 amRNSExscientia - Statement filed for proposed IPO
8th Sep 20211:24 pmRNSExscientia enters $70M collaboration
8th Jul 20217:00 amRNSCamGraPhIC loan facility of up to £1.5 million
15th Jun 20217:00 amRNSPulsiv appoints Adam Westcott as CFO
14th Jun 20217:00 amRNSNandi Proteins appoints David Flower as CEO
11th Jun 20217:00 amRNSPublication of newsletter
24th May 20217:00 amRNSPulsiv complete £1.5m fundraising and appoints CEO
19th May 202111:53 amRNSExscientia collaboration with Bristol Myers Squibb
6th May 20217:00 amRNSThe Vaccine Group appoints Jeremy Salt as CEO
30th Apr 20211:58 pmRNSHolding(s) in Company
28th Apr 20217:01 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.